Corcept Therapeutics Incorporated

Short Term Long Term Short Term Comparison Long Term Comparison

CORT
1d-1.53%
1w-9.07%
1m-0.34%
1y4.42%
CORT
1y4.42%
5y96.52%
10y539.50%
20y92.92%

Bitcoin
-0.82%
-9.09%
-6.40%
106.24%
Bitcoin
106.24%
1,146.32%
11,770.30%
0.00%

Ethereum
-0.90%
-11.75%
-14.49%
45.57%
Ethereum
45.57%
1,828.08%
0.00%
0.00%

Gold
0.26%
2.56%
11.41%
20.52%
Gold
20.52%
88.92%
85.82%
499.35%

Silver
0.47%
4.25%
15.38%
14.30%
Silver
14.30%
94.94%
48.08%
306.93%

Apple
-2.19%
1.78%
0.04%
5.09%
Apple
5.09%
260.11%
-66.73%
39,041.00%

Amazon
-1.68%
-1.44%
4.92%
78.52%
Amazon
78.52%
96.45%
-43.46%
7,943.96%

Microsoft
-1.96%
-2.97%
-0.67%
45.75%
Microsoft
45.75%
259.81%
923.86%
2,532.12%

S&P 500
-1.20%
-2.84%
-1.08%
22.34%
S&P 500
22.34%
74.12%
171.80%
346.13%

Dow & Jones
-0.65%
-2.95%
-2.53%
11.36%
Dow & Jones
11.36%
42.65%
129.74%
261.03%

ATH

ATH Price$33.80
ATH Date2023-09-14
% since ATH-31.51%
% to ATH46.00%

ATL

ATL Price$0.70
ATL Date2006-10-13
% from ATL3,207.14%
Last Low Price$21.1
Last Low Date2024-01-31
% From Last Low9.72%

IPO

IPO Price$12.25
% Current ROI USD188.98%
ATH Price$33.80
% ROI ATH 482,857.14%

[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="CORT"]

Key Data [addtoany]

Current price	$23.15
Sector	Healthcare
Industry	Biotechnology
Today's High/Low	$23.63/$22.91
Volume	724,356.00
Previous Close	$23.51
52 Week High/Low	$34.275/$20.8693
Market Cap	2,440,172,032.00
P/E Ratio	24.6277
Forward P/E 1 Yr.	$71.43
Earnings Per Share(EPS)	$1.38
Annualized Dividend	$0

$23.15

[addtoany]

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States.
The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery.
It is developing relacorilant to treat patients with Cushing’s syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors.
The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays.
Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

Annual Data \| Millions of US $ except per share data	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31	2000-12-31
Cash on hand	$275.96	$206.76	$88.74	$51.54	$40.44	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	$19.93	$17.59	$15.30	$9.86	$6.22	$3.33	-	-	-	-	-	-	-	-	-	-	-	-	-
Inventory	$5.42	$4.73	$4.58	$2.33	$1.68	$1.21	$1.10	$0.85	$0	-	-	-	-	-	-	-	-	-	-
Pre-Paid Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Current Assets	$6.04	$7.74	$2.67	$1.96	$0.64	$1.44	$0.91	$0.62	$0.14	$0.42	$0.55	$1.27	$0.29	$0.34	$0.43	$0.84	$0.17	$0.20	$0.01
Total Current Assets	$307.36	$236.82	$124.19	$65.69	$48.98	$30.23	$58.31	$95.06	$0	-	-	-	-	-	-	-	-	-	-
Property, Plant, And Equipment	$4.50	$0.66	$0.52	$0.21	$0.10	$0.24	$0.20	$0.15	$0.03	$0400000	$0.01	$0.02	$0.03	$0.04	$0.05	-	$0100000	$0.02	$0.03
Long-Term Investments	$39.35	$0	$15.28	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Goodwill And Intangible Assets	-	-	$0	$0	$0	$0	$0	$0	$0	-	-	-	-	-	-	-	-	-	-
Other Long-Term Assets	$61.11	$74.22	$80.55	$2.86	$2.82	$4.16	$4.56	$3.95	$0.03	$0.10	$0.08	$0.18	$0.06	$0.07	$0.06	$0.05	$0.04	$0.03	-
Total Long-Term Assets	$104.95	$74.87	$96.35	$3.06	$0.16	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	$412.31	$311.69	$220.54	$68.75	$51.90	$34.63	$63.08	$99.17	$39.83	$25.10	$24.51	$19.78	$17.74	$9.90	$30.16	$47.77	$11.78	$21.80	$1.05
Total Current Liabilities	$38.84	$35.57	$29.57	$27.37	$20.88	$13.56	$12.74	$8.36	$5.03	$3.86	$2.42	$2.86	$2.99	$3.51	$3.52	$1.82	$1.01	$1.52	$1.24
Long Term Debt	-	-	$0	$0	$12.53	$24.46	$29.32	$29.03	$0	-	-	$0600000	$0.02	$0.03	$0.04	-	$0.52	$0.50	-
Other Non-Current Liabilities	$0.39	$0.24	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Long Term Liabilities	$2.29	$0.24	$0	$0	$12.56	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	$41.13	$35.81	$29.57	$27.37	$33.40	$38.02	$42.06	$37.39	$5.03	$3.86	$2.42	$2.87	$3.01	$3.54	$3.56	$1.82	$1.54	$2.02	$1.24
Common Stock Net	$0.12	$0.12	$0.12	$0.11	$0.11	$0.10	$0.10	$0.10	$0.08	$0.07	$0.06	$0.05	$0.04	$0.03	$0.02	$0.02	$0900000	$0.01	$0900000
Retained Earnings (Accumulated Deficit)	$-23.56	$-117.74	$-193.15	$-322.27	$-330.41	$-324	$-292.62	$0	$0	-	-	-	-	-	-	-	-	-	-
Comprehensive Income	-	-	$0	$0	$0	$0	$0	$0	$0	-	-	-	-	-	-	-	-	-	-
Other Share Holders Equity	$0.26	$-0.07	$-0.08	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Share Holder Equity	$371.18	$275.88	$190.97	$41.38	$18.50	$-3.39	$21.02	$61.78	$34.81	$21.24	$22.09	$16.91	$14.73	$6.36	$26.59	$45.95	$10.24	$19.78	-
Total Liabilities And Share Holders Equity	$412.31	$311.69	$220.54	$68.75	$51.94	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Annual Data \| Millions of US $ except per share data	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31	2000-12-31
Revenue	$306.49	$251.25	$159.20	$81.32	$50.29	$26.55	$10.36	$3.31	$0	-	$0.03	$0.21	$0.48	$0.29	-	-	-	-	-
Cost Of Goods Sold	$5.50	$5.22	$3.55	$2.06	$1.36	$0.74	$0.07	$0.06	$0	-	$20.27	$19.89	$12.71	$25.86	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Research And Development Expenses	$89.02	$75.25	$40.38	$23.84	$15.42	$18.37	$20.47	$14.07	$21	$18.95	$14.40	$14.15	$7.86	$20.83	$17.07	$11.55	$8.11	$13.15	$1.32
SG&A Expenses	$100.36	$81.29	$62.42	$45.24	$36.95	$35.80	$31.38	$25.51	$11.33	$27.43	-	-	-	-	$21.15	$16.04	$9.97	$18.78	$1.89
Other Operating Income Or Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	$194.88	$161.75	$106.35	$71.14	$53.73	$54.17	$51.85	$39.58	$32.33	-	-	-	-	-	-	-	-	-	-
Operating Income	$111.61	$89.50	$52.86	$10.18	$-3.44	$-27.62	$-41.50	$-36.27	$-32.33	-	-	-	-	-	-	-	-	-	-
Total Non-Operating Income/Expense	$5.07	$2.66	$-0.05	-	-	-	-	-	$-0.02	-	-	-	-	-	-	-	-	-	-
Pre-Tax Income	$116.68	$92.15	$52.81	$8.14	$-6.41	$-31.38	$-46.01	$-38.05	$-32.35	-	-	-	-	-	-	-	-	-	-
Income Taxes	$22.50	$16.74	$-76.32	$0	$0	$0	$0	$0	$0	-	-	-	-	-	-	-	-	-	-
Income After Taxes	$22.50	$16.74	$-76.32	$0	$0	$0	$0	$0	$0	-	-	-	-	-	-	-	-	-	-
Other Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income From Continuous Operations	$94.18	$75.41	$129.12	$8.14	$-6.41	$-31.38	$-46.01	$-38.05	$-32.35	-	-	-	-	-	-	-	-	-	-
Income From Discontinued Operations	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	$94.18	$75.41	$129.12	$8.14	$-6.41	$-31.38	$-46.01	$-38.05	$-32.35	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBIT	$111.61	$89.50	$52.86	$10.18	$-3.44	$-27.62	$-41.50	$-36.27	$-32.33	-	-	-	-	-	-	-	-	-	-
Basic Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	$123	$115.03	$125	$116	$107	$101	$100	$93	$83	$68	$52	$47	$34	$23	$23	$23	-	-	-
Basic EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS - Earnings Per Share	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Annual Data \| Millions of US $ except per share data	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31	2000-12-31
Net Income/Loss	$94.18	$75.41	$129.12	$8.14	$-6.41	$-31.38	$-46.01	$-38.05	$-32.35	-	-	-	-	-	-	-	-	-	-
Total Depreciation And Amortization - Cash Flow	$2.17	$0.24	$0.11	$0.09	$3.03	$3.85	$4.52	$1.72	$0300000	-	-	-	-	-	-	-	-	-	-
Change In Accounts Receivable	$-2.34	$-2.29	$-5.44	$-3.64	$-2.89	$-1.91	$0.87	$0.56	$0	-	-	-	-	-	-	-	-	-	-
Change In Inventories	$-1.04	$-7.78	$-2.26	$-0.68	$0.82	$0.25	$-0.88	$-4.66	$0	-	-	-	-	-	-	-	-	-	-
Cash Flow From Operating Activities	$136.12	$115.67	$60.94	$18.39	$3.13	$-27.38	$-37.06	$-36.02	$-27.40	-	-	-	-	-	-	-	-	-	-
Cash Flow From Investing Activities	$-117.83	$-90.77	$-73.46	$-0.19	$-0.02	$-0.17	$-0.13	$-0.15	$-0.03	-	$3.59	$2.33	-	$25.36	$15.11	-	$1.64	-	-
Debt Issuance/Retirement Net - Total	-	-	$-15.13	$-14.78	$-9.21	$-4.86	$-1.03	$29.86	-	-	-	-	-	-	-	-	-	-	-
Total Common And Preferred Stock Dividends Paid	-	-	$0	$0	$0	$0	$0	$0	$0	-	-	-	-	-	-	-	-	-	-
Financial Activities - Other	$-6.09	-	-	-	-	-	-	-	$42.48	-	-	$0600000	$0.02	$0.04	$0.02	$0.06	$0.04	-	-
Cash Flow From Financial Activities	$-28.65	$-14.34	$-7.95	$-7.10	$13.07	$-3.08	$-0.97	$89.57	$42.48	$23	$23.53	$19.32	$18.87	$2.97	$0.01	$49.09	$0.04	$11.80	$2.08
Net Cash Flow	$-10.36	$10.56	$-20.47	$11.10	$16.19	$-30.63	$-38.16	$53.40	$15.06	-	-	-	-	-	-	-	-	-	-
Common Stock Dividends Paid	-	-	$0	$0	$0	$0	$0	$0	$0	-	-	-	-	-	-	-	-	-	-